SCHEMBL6607260

SCHEMBL6607260

N#CC1(c2ccc(NC(=O)OCc3ccccc3)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.55
RAB9A P51151 4/20 0.55
ALDH1A1 P00352 4/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
POLB P06746 1/20 0.54
KDM1A O60341 3/20 0.53
MAOA P21397 2/20 0.53
MAOB P27338 2/20 0.53
RCOR1 Q9UKL0 2/20 0.52
TP53 P04637 3/20 0.51
MAPT P10636 3/20 0.51
TSHR P16473 1/20 0.50
ATM Q13315 1/20 0.50
ROCK2 O75116 1/20 0.49
MGLL Q99685 1/20 0.49
LMNA P02545 2/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6610001 0.82 TP53 (0.51) NPC1RAB9AALDH1A1SMN1; SMN2POLB
SCHEMBL6607532 0.82 NPC1 (0.50) NPC1RAB9AALDH1A1SMN1; SMN2POLB
SCHEMBL6609524 0.82 TP53 (0.50) NPC1RAB9AALDH1A1SMN1; SMN2POLB
SCHEMBL6002580 0.80 KDM1A (0.51) NPC1RAB9AALDH1A1SMN1; SMN2POLB
SCHEMBL5764459 0.80 KDM1A (0.51) NPC1RAB9AALDH1A1SMN1; SMN2POLB
SCHEMBL3864735 0.78 MEN1 (0.60) ALDH1A1MEN1KMT2AKDM1AMAOB
Benzyl Phenylcarbamate SCHEMBL1222943 0.78 POLB (0.78) NPC1RAB9AALDH1A1SMN1; SMN2POLB
SCHEMBL4187427 0.78 POLB (0.61) NPC1RAB9AALDH1A1SMN1; SMN2KMT2A
SCHEMBL2175244 0.77 POLB (0.53) NPC1RAB9AALDH1A1SMN1; SMN2MEN1
SCHEMBL16946758 0.76 POLB (0.59) NPC1RAB9AALDH1A1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1448536-A1 CYCLOPROPYL-CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF Merck & Co., Inc. (US) 2004-08-25 EP disclosed
US-6686363-B2 EFFECTIVE AGAINST MULTI-RESISTANT BACTERIA KYORIN PHARMACEUTICAL CO., LTD. (JP) 2004-02-03 US disclosed
US-20030225107-A1 CYCLOPROPYL CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF MERCK SHARP & DOHME CORP. 2003-12-04 US disclosed
WO-2003048136-A1 CYCLOPROPYL HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF MERCK & CO., INC. (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225107-A1 CYCLOPROPYL CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF ALAD, OXA1L, ECI1 NPC1 1524/4885RAB9A 2945/4885ALDH1A1 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.